[Hyderabad, April 30th, 2025] – The global clinical trials market is experiencing transformative growth, projected to surge from USD 52.8 billion in 2023 to USD 91.1 billion by 2031, expanding at a 7.1% CAGR ClearView Market Insights, 2024.This expansion is driven by advancements in decentralized trials, precision medicine, and AI-driven patient recruitment across three pivotal segments:

Request Sample @ https://clearviewmarketinsights.com/report-details/global-clinical-trials-market/

Decentralized Clinical Trials (DCT) Surge:

• Pfizer’s COVID-19 vaccine trials accelerated using a hybrid DCT model, leading to a 30% reduction in patient dropout rates.
• Medable’s DCT platform facilitated a 40% faster enrollment across oncology and rare disease studies.
• In 2024, FDA guidance formally endorses remote monitoring, driving industry-wide DCT adoption.

Precision Medicine Focus:

• Adaptive Trial Designs: Moderna’s personalized mRNA cancer vaccine trials adopt basket trial models, cutting Phase II timelines by 25%.
• Genomic Screening: Foundation Medicine’s platform integrates genomic profiling to optimize patient stratification in clinical trials.
• Companion Diagnostics: Roche expands its FDA-approved companion diagnostics portfolio to cover emerging immunotherapy candidates.

AI-Driven Patient Recruitment:

• Deep 6 AI’s platform identifies eligible patients 20x faster, boosting enrollment speed by 32% for rare disease trials.
• Trialbee’s AI recruitment tools increase patient diversity, achieving 60% minority representation in U.S.-based trials.
• IBM’s AI algorithms predict site performance, reducing trial site failures by 18%.

2024 Breakthroughs

Commercialization Milestones

Investment & R&D Trends:

• Startup Funding: USD 3.8 billion raised in 2023 for clinical trial tech platforms (e.g., Science 37’s USD 250M Series D).
• Corporate R&D: Up 22% YoY, with:
• IQVIA: USD 400M invested in next-gen clinical trial software.
• Parexel: USD 250M dedicated to expanding DCT capabilities globally.

Executive Insights

• "Decentralization is no longer optional; it is reshaping patient-centricity in every phase of clinical research." — Dr. Michelle Longmire, CEO, Medable
• "AI is helping us build smarter trials—accelerating time-to-market for therapies that patients desperately need." — Dr. Arthur Tzianabos, CEO, Unlearn.AI

Regional Analysis

North America (XX% Market Share):

• NIH’s new funding of USD 2 billion prioritizes decentralized and patient-centric trial initiatives.
• FDA’s Project Optimus reshapes oncology trial design standards, encouraging adaptive methodologies.

Europe (XX% Share):

• EMA’s Remote Monitoring Framework boosts DCT adoption across EU member states.
• Horizon Europe’s €1.5 billion investment supports personalized medicine trials and AI-driven trial management.

Asia-Pacific (XX % Share):

• China’s NMPA fast-tracks approval for DCT models in oncology and rare disease trials.
• India’s CDSCO launches a regulatory sandbox to streamline decentralized trial approvals.

Future Roadmap:

• 2025: AI-driven synthetic control arms adopted in 30% of new oncology trials.
• 2027: Blockchain-based eConsent platforms become industry standard.
• 2030: Personalized multi-omic clinical trials become mainstream, integrating genomics, proteomics, and metabolomics.

Company Spotlight:

1. Medable

• Market Position: Leader in DCT solutions with over 150 deployments globally.
• 2024 Innovation: Launch of "Medable 360," a unified decentralized trial ecosystem.
• Growth Strategy: Forge strategic partnerships with leading CROs to enhance access to underserved populations.

2. AI:

• Breakthrough: First FDA submission using a virtual control arm for Alzheimer's trials.
• Partnerships: Collaborating with top 10 pharma companies on AI-based trial design.

For more insights, visit https://clearviewmarketinsights.com/report-store

About Clearview Market Insights:

Clearview Market Insights is a leading market research and consulting firm providing in-depth industry analysis and strategic recommendations for businesses worldwide.

Media contact:

Bhavani K

Marketing and Sales Head

ClearView Market Insights

Mail: sales@clearviewmarketinsights.com

Phone: +1 917-993-736